載入...
Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
Pembrolizumab has been available for the treatment of radical resectable urothelial carcinoma (UC) when it is exacerbated after chemotherapy since December 2017 in Japan. However, the efficacy of chemotherapy for cases progressing after pembrolizumab is unclear. The present study compared the outcom...
Na minha lista:
| 發表在: | Mol Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
D.A. Spandidos
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7976390/ https://ncbi.nlm.nih.gov/pubmed/33767860 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2021.2253 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|